Wall Street's Mixed Verdict: What Schedule III Rescheduling Actually Means for Cannabis Stocks

The cannabis industry got the headline it's been waiting years for on April 23, 2026: Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. It was a seismic policy shift—arguably the biggest federal move on marijuana since prohibition began—but Wall Street's reaction told a more complicated story than the headlines suggested.

Cannabis stocks surged in premarket trading. Curaleaf Holdings jumped more than 27 percent. The AdvisorShares Pure US Cannabis ETF (MSOS) spiked. For about two hours, it looked like the long-awaited catalyst had finally arrived. Then reality set in. By midday, many of those gains had evaporated, and several major cannabis names turned negative on the session.

So what happened? And more importantly, what does Schedule III actually mean for cannabis investors going forward?

The 280E Relief Is Real—and Significant

The single most tangible benefit of rescheduling is the elimination of IRS Code Section 280E for state-licensed medical cannabis operators. Under the old classification, cannabis companies couldn't deduct standard business expenses like rent, payroll, and marketing because they were technically trafficking in a Schedule I substance. This created effective tax rates of 70 percent or higher for some operators.

With Schedule III status, those deductions become available immediately. For a company like Curaleaf or Green Thumb Industries, which operate dozens of dispensaries and cultivation facilities, 280E relief could mean millions of dollars flowing straight to the bottom line. AdvisorShares estimated in their statement that the rescheduling would "meaningfully improve the financial health of American cannabis operators" and called it an "industry inflection point."

Morgan Stanley analysts noted that 280E relief alone could boost operating margins for multi-state operators (MSOs) by 15 to 25 percentage points, depending on their cost structure and state mix.

Why Stocks Pulled Back Anyway

If the financial benefit is so clear, why did investors sell into the news? Several factors converged.

First, this was a classic "buy the rumor, sell the news" event. Bloomberg had reported the night before that the DOJ was expected to act as soon as Wednesday — as the DEA hearing coverage laid out — and cannabis stocks had already been climbing in anticipation. By the time the official announcement dropped, much of the upside was priced in.

Second, the scope of the rescheduling was narrower than some investors had hoped. The order applies specifically to FDA-approved products containing marijuana and items regulated under a state medical marijuana license. It does not legalize marijuana federally. It does not apply to recreational cannabis. And it does not resolve the fundamental banking challenges that have plagued the industry—though it opens the door wider than ever before.

Third, Smart Approaches to Marijuana (SAM) immediately announced plans for legal action against the order, introducing uncertainty about whether the rescheduling would survive judicial review. While most legal experts believe the DOJ's authority here is solid, the threat of litigation gave cautious investors a reason to take profits.

What Actually Changes for Cannabis Companies

Beyond the 280E tax relief, rescheduling brings several practical changes that will play out over months and years rather than days.

Research access improves dramatically. Under Schedule I, researchers needed special DEA licenses and could only source cannabis from a single federally approved facility at the University of Mississippi. Schedule III classification removes those barriers, opening the door for pharmaceutical companies and universities to conduct large-scale clinical trials. This could eventually lead to more FDA-approved cannabis-derived medicines—a market that could dwarf the current dispensary model.

Banking becomes easier, not automatic. Schedule III doesn't explicitly grant cannabis companies access to traditional banking, but it removes the primary legal justification banks have used to refuse service. Many compliance departments treated cannabis banking as too risky specifically because of its Schedule I status. With that obstacle removed, expect a gradual thawing—though don't expect JPMorgan to start underwriting cannabis IPOs next week.

Institutional investors get a longer leash. Many institutional funds have strict mandates against investing in Schedule I substances. Reclassification to Schedule III eliminates that particular compliance barrier, potentially opening the door for pension funds, endowments, and mainstream mutual funds to take positions in cannabis companies. This could be the most significant long-term impact, as institutional capital typically brings stability, liquidity, and higher valuations.

For a broader view of 4/20 2026 market data, see the industry sales breakdown.

The MSOS ETF: A Barometer Worth Watching

The AdvisorShares Pure US Cannabis ETF has become the de facto barometer for the US cannabis sector. After the rescheduling announcement, MSOS issued a statement calling the move a "historic moment" and noting that it would "remove one of the most significant barriers to financial normalization for the industry."

But MSOS has also been a cautionary tale about the gap between cannabis policy progress and stock performance. The ETF is still down significantly from its 2021 highs, despite a string of positive policy developments. This reflects a market that has learned, sometimes painfully, that regulatory progress doesn't automatically translate into profitable companies.

The lesson for investors: rescheduling is necessary but not sufficient. Cannabis companies still need to demonstrate they can grow revenue, manage costs, and compete in what remains an intensely fragmented market.

What Comes Next: The June Hearings

Perhaps the most important detail in the DOJ's announcement was the mention of expedited hearings set for June to consider broader reclassification of marijuana. This suggests the administration views the April 23 order as a first step rather than the final word.

If those June hearings result in a more comprehensive reclassification—one that includes recreational cannabis—the investment thesis changes dramatically. The total addressable market for recreational cannabis in the US is estimated at $47 billion for 2026 alone, according to BDSA. Federal normalization of that entire market would be a true game-changer.

For now, though, the smart money appears to be watching and waiting. The rescheduling is genuinely significant—historic, even—but the cannabis industry's path from Schedule III to sustainable profitability is longer than a single trading session.

The Bottom Line

The DOJ's rescheduling of medical marijuana to Schedule III is the most important federal cannabis policy change in decades. The 280E tax relief is real and immediate. The downstream effects on banking, research, and institutional investment could reshape the industry over the next two to five years.

But if you're expecting a straight line from here to cannabis stock riches, the market's reaction on April 23 should give you pause. Cannabis investing has always rewarded patience over hype. That hasn't changed—even on a day when the federal government finally started to catch up with what 40 states already knew.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always consult with a qualified financial advisor before making investment decisions.